CareDx Q4 2025 Earnings Call Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2026
0mins
Should l Buy CDNA?
Source: seekingalpha
- Strong Financial Performance: CareDx reported total revenue of $108.4 million in Q4 2025, a 25% increase year-over-year, with testing services revenue at $78.4 million, indicating sustained growth in the kidney testing sector and enhancing its market competitiveness.
- New Product Launch: The company introduced AlloHeme, an AI-powered surveillance solution for detecting relapse post-allogeneic cell transplantation, which identifies relapse a median of 41 days earlier than clinical detection, with commercial introduction targeted for 2027, expanding the product line and market opportunities.
- Optimistic Outlook: CareDx expects total revenue for 2026 to range between $420 million and $444 million, with testing services projected at $306 million to $326 million, reflecting confidence in future growth despite anticipated negative impacts from the LCD policy.
- Management Changes: Keith Kennedy has been appointed as Chief Operating Officer and Chief Financial Officer, succeeding Nathan Smith, and this management transition may influence the company's strategic execution and financial management, further driving innovation in precision diagnostics.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CDNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CDNA
Wall Street analysts forecast CDNA stock price to fall
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 18.745
Low
18.00
Averages
18.00
High
18.00
Current: 18.745
Low
18.00
Averages
18.00
High
18.00
About CDNA
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CareDx Q4 2025 Earnings Call Highlights
- Strong Financial Performance: CareDx reported total revenue of $108.4 million in Q4 2025, a 25% increase year-over-year, with testing services revenue at $78.4 million, indicating sustained growth in the kidney testing sector and enhancing its market competitiveness.
- New Product Launch: The company introduced AlloHeme, an AI-powered surveillance solution for detecting relapse post-allogeneic cell transplantation, which identifies relapse a median of 41 days earlier than clinical detection, with commercial introduction targeted for 2027, expanding the product line and market opportunities.
- Optimistic Outlook: CareDx expects total revenue for 2026 to range between $420 million and $444 million, with testing services projected at $306 million to $326 million, reflecting confidence in future growth despite anticipated negative impacts from the LCD policy.
- Management Changes: Keith Kennedy has been appointed as Chief Operating Officer and Chief Financial Officer, succeeding Nathan Smith, and this management transition may influence the company's strategic execution and financial management, further driving innovation in precision diagnostics.
See More
CareDx (CDNA) Q4 2025 Earnings Call Transcript
See More
CareDx COO Keith Kennedy to Also Serve as CFO Starting February 2026
- Executive Restructuring: CareDx announced that COO Keith Kennedy will also take on the role of CFO effective February 26, 2026, reflecting the company's strategic intent to enhance management efficiency and financial transparency through executive consolidation.
- Background Experience: Kennedy has served as COO since September 2024 and previously held the CFO position at PharmaLogic Holdings Corp, bringing extensive financial management expertise that could aid CareDx in achieving higher professionalism in future financial decisions.
- CFO Departure: Current CFO Nathan Smith announced his resignation during the company's quarterly earnings call, indicating a shift in the executive team that may affect investor confidence regarding the company's stability.
- Financial Outlook: CareDx is set to release its preliminary fourth quarter and full year 2025 financial results, and the new executive structure could influence market expectations for the company's future financial performance, particularly amid ongoing regulatory risks.
See More
CareDx Appoints New CFO to Enhance Operational Efficiency
- Executive Transition: CareDx announced that Chief Operating Officer Keith Kennedy will also take on the role of Chief Financial Officer effective February 26, 2026, aiming to integrate financial management and enhance operational efficiency while improving financial decision-making capabilities.
- Extensive Experience: Kennedy brings over 20 years of executive experience in healthcare, having served as CFO at PharmaLogic Holdings and held various executive roles at Veracyte, showcasing his strong background in financial and operational management.
- Strategic Focus: This appointment not only recognizes Kennedy's capabilities but also reflects CareDx's emphasis on efficient financial management during its transformation, aiming to support ongoing innovation and market expansion in the field of transplant medicine.
- Future Outlook: With Kennedy's addition, CareDx plans to enhance transparency and compliance in future financial reporting to address market changes and potential risks, ensuring the company maintains its competitive edge in the rapidly evolving healthcare market.
See More
CareDx Appoints New CFO to Strengthen Financial Leadership
- Executive Transition: CareDx announced that Chief Operating Officer Keith Kennedy will also assume the role of Chief Financial Officer effective February 26, 2026, aiming to enhance financial management capabilities through his 20 years of experience in the healthcare sector.
- Financial Background: Prior to this role, Kennedy served as CFO at PharmaLogic Holdings Corp and held various executive positions at Veracyte, bringing a wealth of financial and operational expertise that will provide strategic advantages to CareDx.
- Company Mission: CareDx focuses on delivering precision medicine solutions for transplant patients, with its non-invasive molecular testing and digital health technologies leading the way in heart, kidney, and lung transplants, aimed at improving patient outcomes.
- Forward-Looking Statements: The company highlighted in its press release that future performance may be influenced by economic and market factors, urging investors to exercise caution regarding forward-looking statements to avoid undue reliance on potentially inaccurate forecasts.
See More
CareDx Reports Q4 Earnings with Revenue Beat but EPS Miss
- Earnings Highlights: CareDx's Q4 non-GAAP EPS of $0.12 fell short of expectations by $0.11, indicating pressure on profitability that could affect investor confidence.
- Revenue Growth: The company reported Q4 revenue of $108.4 million, a 25.2% year-over-year increase, surpassing market expectations by $5.66 million, reflecting strong demand for its products and driving overall performance.
- Clinical Data Discussion: CareDx discussed the AlloHeme clinical validation data review and launch timeline in AML and MDS post-cell therapy, showcasing proactive progress in new product development despite regulatory risks.
- Future Outlook: CareDx has reached an inflection point, and while regulatory risks persist, the preliminary forecast for 2025 financial results indicates confidence in future growth, potentially attracting more investor interest.
See More
CareDx Q4 2025 Earnings Call Highlights
- Strong Financial Performance: CareDx reported total revenue of $108.4 million in Q4 2025, a 25% increase year-over-year, with testing services revenue at $78.4 million, indicating sustained growth in the kidney testing sector and enhancing its market competitiveness.
- New Product Launch: The company introduced AlloHeme, an AI-powered surveillance solution for detecting relapse post-allogeneic cell transplantation, which identifies relapse a median of 41 days earlier than clinical detection, with commercial introduction targeted for 2027, expanding the product line and market opportunities.
- Optimistic Outlook: CareDx expects total revenue for 2026 to range between $420 million and $444 million, with testing services projected at $306 million to $326 million, reflecting confidence in future growth despite anticipated negative impacts from the LCD policy.
- Management Changes: Keith Kennedy has been appointed as Chief Operating Officer and Chief Financial Officer, succeeding Nathan Smith, and this management transition may influence the company's strategic execution and financial management, further driving innovation in precision diagnostics.
See More
CareDx (CDNA) Q4 2025 Earnings Call Transcript
See More
CareDx COO Keith Kennedy to Also Serve as CFO Starting February 2026
- Executive Restructuring: CareDx announced that COO Keith Kennedy will also take on the role of CFO effective February 26, 2026, reflecting the company's strategic intent to enhance management efficiency and financial transparency through executive consolidation.
- Background Experience: Kennedy has served as COO since September 2024 and previously held the CFO position at PharmaLogic Holdings Corp, bringing extensive financial management expertise that could aid CareDx in achieving higher professionalism in future financial decisions.
- CFO Departure: Current CFO Nathan Smith announced his resignation during the company's quarterly earnings call, indicating a shift in the executive team that may affect investor confidence regarding the company's stability.
- Financial Outlook: CareDx is set to release its preliminary fourth quarter and full year 2025 financial results, and the new executive structure could influence market expectations for the company's future financial performance, particularly amid ongoing regulatory risks.
See More
CareDx Appoints New CFO to Enhance Operational Efficiency
- Executive Transition: CareDx announced that Chief Operating Officer Keith Kennedy will also take on the role of Chief Financial Officer effective February 26, 2026, aiming to integrate financial management and enhance operational efficiency while improving financial decision-making capabilities.
- Extensive Experience: Kennedy brings over 20 years of executive experience in healthcare, having served as CFO at PharmaLogic Holdings and held various executive roles at Veracyte, showcasing his strong background in financial and operational management.
- Strategic Focus: This appointment not only recognizes Kennedy's capabilities but also reflects CareDx's emphasis on efficient financial management during its transformation, aiming to support ongoing innovation and market expansion in the field of transplant medicine.
- Future Outlook: With Kennedy's addition, CareDx plans to enhance transparency and compliance in future financial reporting to address market changes and potential risks, ensuring the company maintains its competitive edge in the rapidly evolving healthcare market.
See More
CareDx Appoints New CFO to Strengthen Financial Leadership
- Executive Transition: CareDx announced that Chief Operating Officer Keith Kennedy will also assume the role of Chief Financial Officer effective February 26, 2026, aiming to enhance financial management capabilities through his 20 years of experience in the healthcare sector.
- Financial Background: Prior to this role, Kennedy served as CFO at PharmaLogic Holdings Corp and held various executive positions at Veracyte, bringing a wealth of financial and operational expertise that will provide strategic advantages to CareDx.
- Company Mission: CareDx focuses on delivering precision medicine solutions for transplant patients, with its non-invasive molecular testing and digital health technologies leading the way in heart, kidney, and lung transplants, aimed at improving patient outcomes.
- Forward-Looking Statements: The company highlighted in its press release that future performance may be influenced by economic and market factors, urging investors to exercise caution regarding forward-looking statements to avoid undue reliance on potentially inaccurate forecasts.
See More
CareDx Reports Q4 Earnings with Revenue Beat but EPS Miss
- Earnings Highlights: CareDx's Q4 non-GAAP EPS of $0.12 fell short of expectations by $0.11, indicating pressure on profitability that could affect investor confidence.
- Revenue Growth: The company reported Q4 revenue of $108.4 million, a 25.2% year-over-year increase, surpassing market expectations by $5.66 million, reflecting strong demand for its products and driving overall performance.
- Clinical Data Discussion: CareDx discussed the AlloHeme clinical validation data review and launch timeline in AML and MDS post-cell therapy, showcasing proactive progress in new product development despite regulatory risks.
- Future Outlook: CareDx has reached an inflection point, and while regulatory risks persist, the preliminary forecast for 2025 financial results indicates confidence in future growth, potentially attracting more investor interest.
See More
